A key requirement for the PD-1/PD-L1 blocking response is that tumor-specific T cells in the patient are inhibited by PD-1, and PD-L1 expression in the tumor inhibits PD-1+ T cells at sites that require antitumor activity (Poggio et al., 2019). Here, CD274 is linked to neoplasm.